Invasive cutaneous aspergillosis complicating immunosuppressive therapy for recalcitrant pemphigus vulgaris.
Thakur
B K
BK
Division of Allergy and Clinical Immunology, University Hospital and the State University of New York (Health Science Center), Stony Brook, USA.
Bernardi
D M
DM
Murali
M R
MR
McClain
S A
SA
Clark
R A
RA
D000328:Adult; D001228:Aspergillosis / Q000209:etiology*; D001379:Azathioprine / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects; D003881:Dermatomycoses / Q000209:etiology*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D010392:Pemphigus / Q000628:therapy*; D010956:Plasmapheresis; D011241:Prednisone / Q000008:administration & dosage
D007136:Immunoglobulins; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003520:Cyclophosphamide; D001379:Azathioprine; D011241:Prednisone